FDA Grants Investigational New Drug Status to Combination of ACTR707 and Rituxan for Lymphoma
News
The U.S. Food and Drug Administration has granted Investigational New Drug status to Unum Therapeutics’ ACTR707, in combination with Genentech’s Rituxan (rituximab), for treating non-Hodgkin lymphoma. Regulators’ approval applies to relapsed or refractory ... Read more